Based in Sittingbourne, Kent, Cirrus is both US Food and Drug Administration (FDA) and UK Medicines and Healthcare product Regulatory Agency (MHRA) audited and approved for pharmaceutical testing and provides independent testing for some of the major brand leading pharmaceutical companies. The company specialises in stability trials, raw materials and batch release testing, as well as method development and validation. Outsourcing stability and analytical testing of pharmaceutical products enables companies to free-up valuable laboratory space for core activities such as research and development and can offer substantial cost savings in removing the need for expensive and specialist testing equipment. Cirrus joins Bodycote's other recent laboratory acquisitions from the food industry - Law Laboratories and Allied Laboratories - under the company's Health Sciences Division. David Clapperton, health science director at Bodycote, said: "The acquisition of Cirrus is another important step for Bodycote Materials Testing. Cirrus complements our existing pharmaceutical testing facilities in Newbridge and Windsor and strengthens our pharma testing offering in the UK as part of our group strategy to become leading experts in laboratory testing." The management team, and staff of Cirrus Laboratories will remain unchanged and the laboratory will continue be based at its facility at Sittingbourne Research Centre. The combined company will now trade as Bodycote Cirrus, according to Paul Walsh, Cirrus' managing director. External links to companies or organisations mentioned in thisstory: Cirrus Laboratories Bodycote
